查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747645

全球綜合多重診斷市場

Syndromic Multiplex Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 274 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球綜合多重診斷市場規模將達 38 億美元

全球綜合多重診斷市場規模預計在2024年為27億美元，預計到2030年將達到38億美元，在分析期間（2024-2030年）的複合年成長率為5.6%。呼吸系統疾病是本報告分析的細分市場之一，預計其複合年成長率為4.4%，到分析期結束時將達到16億美元。胃腸道疾病細分市場在分析期間的複合年成長率預計為7.4%。

美國市場規模估計為 7.364 億美元，中國市場預計複合年成長率為 8.7%

美國綜合多重診斷市場規模預計在2024年達到7.364億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到7.482億美元，在2024-2030年的分析期內，複合年成長率為8.7%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為2.8%和5.5%。在歐洲，預計德國市場的複合年成長率為3.6%。

全球「綜合多重診斷」市場—主要趨勢與促進因素摘要

連接複用技術將如何徹底改變疾病的快速檢測？

隨著病原體的快速進化和對就地檢驗需求的不斷成長，症候群多重診斷已成為臨床診斷領域的重大變革。與傳統的單檢測單病原體模型不同，症候群面板可以同時檢測導致特定臨床症候群的多種病原體，例如呼吸道感染疾病、胃腸道疾病和中樞神經系統疾病。事實證明，這項技術在急救護理環境中至關重要，因為速度和準確性決定了治療結果。最近的進展將測試週轉時間縮短至一小時以內，有助於及時進行臨床決策。 COVID-19 為提高全球對多重檢測的認知和採用提供了前所未有的催化劑。 FDA 和 CE 等監管機構已快速核准多重診斷面板，鼓勵其擴大臨床應用。

多重診斷在兒科護理和免疫力缺乏的患者群體中尤其重要。透過單次檢測即可識別合併感染的能力顯著減少了不必要的治療，並有助於對抗抗生素抗藥性。新興市場的企業正在利用微型平台進行創新，以減少設備佔用空間並提高其在分散環境中的可近性。值得注意的是，一些企業正在利用人工智慧來增強解讀演算法並提供即時決策支援。雲端基礎的數據與醫院資訊系統的整合也是一項重大突破，實現了縱向病患監測和流行病學追蹤。隨著資源匱乏的醫療保健系統需求的不斷成長，人們正在開發具有成本效益的可攜式模型，以填補偏遠地區的診斷空白。

自動化和人工智慧能否彌補檢查能力的差距？

人工智慧和自動化在綜合多重診斷中的作用正日益凸顯。如今，先進的平台已整合機器人分裝、整合式聚合酵素連鎖反應熱迴圈儀和自動化結果報告功能，顯著減少人為干預並最大限度地降低錯誤率。人工智慧驅動的系統透過解析複雜資料集並更準確地解釋模糊結果，增強了病原體識別能力。這些發展顯著提高了通量，使得在流行病期間和高容量臨床實驗室中開展大規模篩檢計畫成為可能。機器學習還透過分析假陽性和假陰性率隨時間的變化來輔助持續的軟體最佳化，從而提高演算法的準確性。

與遠端醫療的整合進一步提升了症候群檢測的效用，使醫療服務提供者能夠遠端啟動和解讀檢測結果。這尤其推動了行動醫療單位和缺乏實驗室專業知識的農村地區診斷的使用案例。同時，症候群系統的可擴展性也吸引了軍事和災難應變組織的關注，他們重視在惡劣環境下的便攜性和效率。新興企業和科技公司正在積極進入該領域，通常與生物技術公司合作，共同開發整合診斷和治療計劃的混合平台。資料安全和互通性如今已成為創新的核心，人們正在探索區塊鏈和分散式帳本技術，以確保共用生態系統中檢測結果的完整性。

除了感染疾病以外，還有什麼因素推動了人們採用該技術？

雖然症候群多重診斷傳統上側重於感染疾病，但最近的突破已將其應用範圍從感染疾病擴展到腫瘤學、藥物基因組學和自體免疫疾病等領域。目前，多重檢測組已開發用於評估基因標記、腫瘤突變和免疫反應指標，開闢了個人化醫療的新領域。使用多重PCR和次世代定序組進行癌症分析，使臨床醫生能夠在單次檢測中提供基於腫瘤生物學的綜合治療。同樣，自體免疫檢測組可以透過同時檢測多種生物標記物，幫助更有效診斷狼瘡和類風濕性關節炎等重疊症候群。

在新生兒加護病房(NICU)，多重檢測有助於快速診斷性行為感染和代謝紊亂，從而及時介入。在藥物基因組學領域，這些檢測用於評估患者對藥物的獨特反應，有助於最佳化劑量並減少副作用。這在多重用藥常見的慢性病管理中尤其重要。人們也越來越關注將症候群診斷與穿戴式健康技術相結合，以創建主動監測系統，這可能會重新定義慢性病的追蹤和復發預測。製藥公司正在與診斷實驗室合作，將多重檢測納入臨床試驗，以便對患者進行分層並更有效地監測反應。

綜合多重診斷市場的成長受到多種因素的推動…

症候群多重診斷市場的成長受到多種因素的驅動，這些因素源自於技術進步、醫療基礎設施趨勢和不斷發展的臨床實踐。最重要的因素是醫院和門診對快速且全面的診斷解決方案的需求日益成長。隨著醫療保健系統優先考慮效率，多重平台正在取代傳統的培養和單一病原體檢測，以減輕實驗室的診斷負擔。微流體、實驗室晶片平台和整合生物感測器等技術創新正在實現診斷系統的微型化，從而提高其在農村和偏遠地區的普及率。感染疾病的激增，加上抗生素抗藥性的上升，推動了對能夠快速區分病毒和細菌病因的檢測的需求。

急診、ICU 和門診的最終需求也在成長，尤其關注感染疾病、感染疾病和性行為感染感染。消費者行為也在發生變化，大眾對早期診斷和預防性篩檢的認知不斷提高。政府主導的篩檢計劃和報銷政策，尤其是在北美和歐洲，進一步推動了這一趨勢。兒科和老年人群是推動採用的關鍵人群，因為他們都容易受到疾病快速進展的影響。此外，新興市場的全球衛生計畫正在人道行動和大流行病防範計畫中引入多重診斷。最後，領先診斷產品製造商的策略投資以及公共衛生機構和診斷產品開發商之間日益加強的合作，正在加速產品平臺，使市場格局保持強勁和競爭力。

部分

類型（呼吸系統、消化器官系統、中樞神經系統、其他類型）、最終使用者（醫院、診斷實驗室、其他最終使用者）

受訪企業範例（共34家）

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioFire Diagnostics（bioMerieux SA）
  • Bio-Rad Laboratories, Inc.
  • Cepheid（A subsidiary of Danaher）
  • Curetis（A subsidiary of OpGen, Inc.）
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP35854

Global Syndromic Multiplex Diagnostics Market to Reach US$3.8 Billion by 2030

The global market for Syndromic Multiplex Diagnostics estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Respiratory Disease, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Gastrointestinal Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$736.4 Million While China is Forecast to Grow at 8.7% CAGR

The Syndromic Multiplex Diagnostics market in the U.S. is estimated at US$736.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$748.2 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global "Syndromic Multiplex Diagnostics" Market - Key Trends & Drivers Summarized

How Is Multiplexing Revolutionizing Rapid Disease Detection?

In an era of rapidly evolving pathogens and increasing demand for point-of-care testing, syndromic multiplex diagnostics has emerged as a transformative force in clinical diagnostics. Unlike traditional one-pathogen-per-test models, syndromic panels enable simultaneous detection of multiple pathogens responsible for a specific clinical syndrome, such as respiratory infections, gastrointestinal diseases, or central nervous system disorders. The technology has proven vital in emergency care settings where speed and accuracy can determine treatment outcomes. Recent advancements have reduced test turnaround times to under an hour, facilitating timely clinical decisions. COVID-19 served as an unprecedented catalyst, heightening global awareness and adoption of multiplex testing. Regulatory bodies like the FDA and CE have fast-tracked approvals for multiplex diagnostic panels, encouraging wider clinical application.

Multiplex diagnostics are particularly critical in pediatric care and immunocompromised patient populations, where co-infections are common and symptoms may be atypical. The ability to identify co-infections through a single test has drastically reduced the number of unnecessary treatments, helping combat antimicrobial resistance. Emerging market players are innovating with miniaturized platforms, reducing device footprint and increasing accessibility in decentralized settings. Notably, companies are leveraging AI to enhance interpretation algorithms and provide real-time decision support. Cloud-based data integration with hospital information systems is another major breakthrough, enabling longitudinal patient monitoring and epidemiological tracking. With growing demand from low-resource healthcare systems, cost-effective portable models are being developed to bridge diagnostic gaps in remote regions.

Can Automation and AI Bridge Laboratory Capacity Gaps?

The role of artificial intelligence and automation in syndromic multiplex diagnostics is gaining considerable momentum. Advanced platforms now incorporate robotic pipetting, integrated thermal cyclers, and automated result reporting, greatly reducing human intervention and minimizing error rates. AI-driven systems enhance pathogen identification by parsing through complex data sets to interpret ambiguous results more accurately. These developments have significantly expanded throughput, making large-scale screening programs feasible during epidemics or in high-volume clinical laboratories. Machine learning is also aiding in continuous software optimization by analyzing false-positive and false-negative rates over time to refine algorithm accuracy.

Telemedicine integration has further propelled the utility of syndromic testing, allowing healthcare providers to initiate and interpret tests remotely. In particular, this has boosted use cases in mobile health units and rural diagnostics where lab specialists are scarce. Meanwhile, the scalability of syndromic systems is attracting attention from military and disaster response organizations, who value portability and efficiency in austere environments. Start-ups and tech companies are entering the space aggressively, often partnering with biotech firms to co-develop hybrid platforms that integrate diagnostics with treatment planning. Data security and interoperability are now central to innovation, with blockchain and decentralized ledgers being explored to ensure test result integrity in shared ecosystems.

What’s Driving Adoption Beyond Infectious Diseases?

While syndromic multiplex diagnostics has traditionally focused on infectious diseases, recent breakthroughs are expanding its use into non-infectious realms such as oncology, pharmacogenomics, and autoimmune disorders. Multiplex panels are now being developed to assess genetic markers, tumor mutations, and immune response indicators, opening up new frontiers in personalized medicine. Cancer profiling using multiplex PCR or next-gen sequencing panels allows clinicians to tailor treatments based on comprehensive tumor biology in a single run. Similarly, autoimmune panels help diagnose overlapping syndromes like lupus and rheumatoid arthritis more effectively by detecting multiple biomarkers simultaneously.

In neonatal intensive care units (NICUs), multiplex testing is helping to rapidly diagnose congenital infections or metabolic disorders, ensuring timely interventions. In the pharmacogenomics sector, these tests are used to evaluate patient-specific responses to drugs, aiding in dose optimization and reducing adverse drug reactions. This is especially pertinent in chronic disease management where polypharmacy is common. There is also a growing interest in combining syndromic diagnostics with wearable health tech to create proactive monitoring systems, which could redefine chronic disease tracking and relapse prediction. Pharmaceutical companies are collaborating with diagnostic labs to integrate multiplex testing into clinical trials to stratify patients and monitor responses more effectively.

The Growth in the Syndromic Multiplex Diagnostics Market Is Driven by Several Factors…

The growth in the syndromic multiplex diagnostics market is driven by several factors rooted in technological advancements, healthcare infrastructure trends, and evolving clinical practices. The most significant driver is the increasing demand for rapid, comprehensive diagnostic solutions in both hospital and outpatient settings. As healthcare systems prioritize efficiency, multiplex platforms are replacing traditional culture and single-pathogen tests, reducing the diagnostic burden on laboratories. Innovations in microfluidics, lab-on-chip platforms, and integrated biosensors have enabled the miniaturization of diagnostic systems, increasing their availability in decentralized and rural locations. The proliferation of infectious diseases-coupled with rising antibiotic resistance-has intensified the need for tests that can distinguish between viral and bacterial etiologies swiftly.

End-use demand from emergency departments, ICUs, and ambulatory clinics continues to rise, with particular emphasis on respiratory, gastrointestinal, and sexually transmitted infections. Consumer behavior is also evolving, with increasing public awareness of early diagnosis and preventive screening. This is further supported by government-led screening programs and reimbursement policies, especially in North America and Europe. Pediatric and geriatric populations-both vulnerable to rapid disease progression-are key demographics driving adoption. Additionally, global health initiatives in emerging markets are deploying multiplex diagnostics in humanitarian and pandemic preparedness programs. Finally, strategic investments by major diagnostic players and rising collaborations between public health agencies and diagnostic developers are accelerating product pipelines, ensuring a robust and competitive market landscape.

SCOPE OF STUDY:

The report analyzes the Syndromic Multiplex Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Respiratory, Gastrointestinal, Central Nervous System, Other Types); End-Use (Hospitals, Diagnostics Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company (BD)
  • Biocartis
  • BioFire Diagnostics (bioMerieux SA)
  • Bio-Rad Laboratories, Inc.
  • Cepheid (A subsidiary of Danaher)
  • Curetis (A subsidiary of OpGen, Inc.)
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Syndromic Multiplex Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Integration of Syndromic Panels in Emergency Care Propels Market Growth
    • Rising Demand for Rapid, Point-of-Care Testing Accelerates Technology Adoption
    • Increased Incidence of Multi-Pathogen Infections Spurs Adoption of Multiplex Solutions
    • Growing Antimicrobial Resistance Strengthens Business Case for Syndromic Testing
    • Automation and Workflow Efficiency in Labs Drives Syndromic Diagnostic Uptake
    • Regulatory Push for Early Disease Detection Expands Market Opportunities
    • Miniaturization and Portability of Devices Drive Penetration in Remote Settings
    • Hospital Consolidation Trends Throw the Spotlight on Integrated Diagnostic Platforms
    • AI Integration in Diagnostic Decision Support Spurs Innovation in Test Panels
    • Expanding Applications in Veterinary and Food Safety Diagnostics Fuel Market Growth
    • Increased Reimbursement Support Across Developed Markets Drives Adoption
    • Rising Awareness Among Clinicians and Patients Accelerates Utilization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Syndromic Multiplex Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Gastrointestinal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Central Nervous System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION